For children born with a rare form of inherited blindness called Leber congenital amaurosis type 16 (LCA16), the genetic culprit can be a single miswritten instruction in their DNA — a so-called “nonsense mutation” that tells the cell to stop building a critical protein before it’s finished. The result is a truncated, nonfunctional protein, a retina that cannot do its job, and progressive loss of sight with no approved treatment.
A paper by Pawan Shahi and Enes Akyuz, co-first authors, published on June 9, 2026, in Signal Transduction and Targeted Therapy — one of the highest-impact journals in biomedical science — reports a proof-of-concept therapy that overrides that premature stop signal, restores the missing protein, and measurably improves retinal function in patient-derived cells and in a mouse model of the disease. The senior author is Bikash Pattnaik, PhD, a professor in the Division of Neonatology and Newborn Nursery, with a joint appointment in the Department of Ophthalmology and Visual Sciences. He is also clinical director of visual electrophysiology at UW Health, and holder of the Retina Research Foundation Daniel M. Albert Chair at the McPherson Eye Research Institute.
The protein at the center of this story is Kir7.1, a potassium ion channel expressed in the retinal pigment epithelium (RPE) — the layer of cells that supports and sustains the light-sensing photoreceptors. In LCA16 patients, a specific nonsense mutation in the gene KCNJ13 causes the cell’s protein-building machinery to stop prematurely, leaving Kir7.1 incomplete and nonfunctional. Without a working channel, the RPE deteriorates, photoreceptors die, and vision is lost.
The Pattnaik Research Group’s approach does not edit or replace the faulty gene. Instead, it deploys a molecule the cell already uses — transfer RNA, or tRNA — in an engineered form. Transfer RNAs are cellular workhorses that carry amino acids to the ribosome, where proteins are built. The team designed an anticodon-engineered suppressor tRNA (ACE-tRNA) that specifically recognizes the premature stop codon in KCNJ13 messenger RNA and, rather than halting production, inserts the correct amino acid, allowing the ribosome to continue building a full-length, functional Kir7.1 protein. The engineered tRNA is delivered into the cell via a helper-dependent adenovirus (HDAd), a viral vehicle chosen for its large cargo capacity and strong safety record in preclinical work.
In patient-derived stem cell models of LCA16, treatment with the ACE-tRNA restored Kir7.1 protein to approximately 40% of normal levels — a 24-fold increase — and rescued the protein’s proper location in the cell membrane, a prerequisite for its function. Electrophysiology measurements confirmed that the restored channels worked. The treated cells also regained the ability to perform a critical housekeeping task: clearing away and recycling the worn-out tips of photoreceptor cells, a function that untreated LCA16 cells had largely lost. In mice, subretinal delivery of the engineered tRNA produced measurable recovery of RPE electrical responses over 14 weeks, with no evidence of retinal toxicity.
The implications of this work extend well beyond LCA16. Nonsense mutations are not unique to this one disease — they account for an estimated 15% to 20% of all inherited disorders, including cystic fibrosis, Duchenne muscular dystrophy, hemophilia, and many ultra-rare diseases.
Because the ACE-tRNA strategy targets the underlying problem caused by nonsense mutations, rather than a single disease gene, Pattnaik envisions it as more than a single treatment: “Our vision is to create a ‘one-for-many’ therapeutic platform that benefits multiple patient populations affected by nonsense mutations, including disorders that are often overlooked due to their small market size,” he said.
This matters especially for patients with ultra-rare conditions, who are often invisible to pharmaceutical development because their numbers are too small to attract commercial investment. The paper explicitly frames the work as a health equity issue: scalable translational therapies may be the only realistic path to treatment for some communities.
This research and publication is the product of a large, cross-institutional collaboration, including researchers from the University of Iowa and the University of North Carolina at Chapel Hill, and represents years of innovative work and breakthroughs by Pattnaik’s trainees and members of the Gamm Lab of David Gamm, MD, PhD, professor in the Department of Ophthalmology and Visual Sciences. For families living with the effects of LCA16 and other causes of Leber congenital amaurosis — including one family in Portugal that reached out to the lab after learning of the research — the study offers the latest credible evidence that a treatment for the disorder may one day be possible.